Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
Open Access
- 21 March 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (6)
Abstract
Background: There are limited data on risk of arrhythmias among patients with lymphoproliferative disorders. We designed this study to determine the risk of atrial and ventricular arrhythmia during treatment of lymphoma in a real‐world setting. Methods and Results: The study population comprised 2064 patients included in the University of Rochester Medical Center Lymphoma Database from January 2013 to August 2019. Cardiac arrhythmias—atrial fibrillation/flutter, supraventricular tachycardia, ventricular arrhythmia, and bradyarrhythmia—were identified using International Classification of Diseases, Tenth Revision ( ICD‐10 ) codes. Multivariate Cox regression analysis was used to assess the risk of arrhythmic events with treatments categorized as Bruton tyrosine kinase inhibitor (BTKi), mainly ibrutinib/non‐BTKi treatment versus no treatment. Median age was 64 (54–72) years, and 42% were women. The overall rate of any arrhythmia at 5 years following the initiation of BTKi was (61%) compared with (18%) without treatment. Atrial fibrillation/flutter was the most common type of arrhythmia accounting for 41%. Multivariate analysis showed that BTKi treatment was associated with a 4.3‐fold ( P P P P <0.001). Conclusions: Our study identifies a high burden of arrhythmic events after initiation of treatment, which is most pronounced among patients treated with the BTKi ibrutinib. Patients undergoing treatments for lymphoma may benefit from prospective focused cardiovascular monitoring prior, during, and after treatment regardless of arrhythmia history.Keywords
This publication has 24 references indexed in Scilit:
- The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysisBlood, 2016
- Cancer Chemotherapy and Cardiac Arrhythmias: A ReviewDrug Safety, 2015
- Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signalingBlood, 2014
- Cancer drugs and the heart: importance and managementEuropean Heart Journal, 2012
- Cancer treatment and survivorship statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Cardiovascular effects of systemic cancer treatmentCancer Treatment Reviews, 2011
- Introducing a new entity: chemotherapy-induced arrhythmiaEP Europace, 2009
- Cardiovascular Complications of Cancer TherapyJACC, 2009
- Cardiotoxicity of Cancer TherapyJournal of Clinical Oncology, 2005
- Analysis of mortality events in the multicenter automatic defibrillator implantation trial (MADIT-II)JACC, 2004